Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$29.04 USD

29.04
4,151,466

-0.05 (-0.17%)

Updated Sep 30, 2024 11:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

GSK's RSV Vaccine Candidate Shows High Efficacy in Older Adults

by Zacks Equity Research

GSK's pivotal phase III AReSVi-006 study evaluating its respiratory syncytial virus (RSV) vaccine candidate in adults aged 60 years and above met its primary endpoint.

The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna, Merck and GSK

by Zacks Equity Research

Pfizer, BioNTech, Moderna, Merck and GSK are included in this Analyst Blog.

Sundeep Ganoria headshot

FDA Allows Emergency Use of Omicron-Based COVID Jabs in Kids

by Sundeep Ganoria

Anticipating a surge of COVID-19 infections later this year, the FDA broadens the label of authorized Omicron-based BA.4/BA.5 adapted bivalent boosters to include children as young as five years.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Oks Omicron Jabs for Kids, MRK, MRNA Partner for Cancer Jab

by Kinjel Shah

FDA grants emergency approval to Pfizer (PFE) and Moderna's (MRNA) Omicron BA.4, BA.5 adapted COVID-19 booster for use in kids. Merck (MRK) and Moderna to jointly develop an mRNA-based cancer vaccine.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Novavax's (NVAX) COVID-19 Booster Recommended in Switzerland

by Zacks Equity Research

The Federal Office of Public Health in Switzerland recommends Novavax's (NVAX) COVID-19 vaccine, Nuvaxovid, as a booster for both heterologous and homologous use in adults aged 18 years and older.

The Zacks Analyst Blog Highlights NVIDIA, Pfizer, Citigroup, Humana, and Canadian Natural Resources

by Zacks Equity Research

NVIDIA, Pfizer, Citigroup, Humana, and Canadian Natural Resources are included in this Analyst Blog.

Pfizer (PFE) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed at $41.75 in the latest trading session, marking a -1.35% move from the prior day.

Sheraz Mian headshot

Top Analyst Reports for NVIDIA, Pfizer & Citigroup

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Pfizer Inc. (PFE) and Citigroup Inc. (C).

Why Pfizer (PFE) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know

by Zacks Equity Research

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Value Trader Highlights: ExxonMobil, Pfizer, Union Pacific, Cisco and PNC Financial

by Zacks Equity Research

ExxonMobil, Pfizer, Union Pacific, Cisco and PNC Financial are part of the Zacks Value Trader blog.

Derek Lewis headshot

These 3 S&P 500 Companies Are Cash-Generating Machines

by Derek Lewis

Let's face it - searching for stocks is difficult, especially with so many options available. One way to cut out the bad apples is by focusing on stocks with strong free cash flow.

Tracey Ryniec headshot

300th Episode: Buffett's 2008 Lessons

by Tracey Ryniec

Scared of the sell-off? Investors were scared in 2008 too. Here's what Buffett said to do.

Biohaven (BHVN) Stock Up on Spin-Off Transaction Finalization

by Zacks Equity Research

The newly spun-off Biohaven Ltd. (BHVN) advances a portfolio of non-CGRP pipelines targeting neurological and neuropsychiatric indications.

3 Top Dividend Stocks to Maximize Your Retirement Income

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Is Exelixis' (EXEL) Growth Story Likely to Continue?

by Zacks Equity Research

Exelixis' (EXEL) efforts to expand Cabometyx's label and develop additional drugs to expand its portfolio should reap rewards for the company.

GSK's Key Drugs to Drive Sales in a Sluggish Second Half

by Zacks Equity Research

GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up for the lower sales of established drugs due to generic erosion.

Why Novavax's (NVAX) COVID Vaccine Struggles for Market Share?

by Zacks Equity Research

Despite being the first protein-based COVID-19 vaccine in many markets, Novavax's (NVAX) delayed product launch severely affected the company's prospects.

Shaun Pruitt headshot

Should Investors Buy Bristol Myers Squibb Stock?

by Shaun Pruitt

BMY's YTD performance indicates the stock has been a viable hedge against inflation because people can ill afford to cut back on health-focused spending.

Pfizer (PFE) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed the most recent trading day at $44.14, moving +0.87% from the previous trading session.

Biohaven Pharma's (BHVN) ALS Study Fail to Meet Both Endpoints

by Zacks Equity Research

Biohaven Pharmaceuticals (BHVN) suffers a setback as verdiperstat fails to meet the primary and secondary endpoints in an ALS study.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster

by Zacks Equity Research

The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222, designed to target the Omicron BA.4 and BA.5 subvariants.

Pfizer (PFE), BNTX Seek EU Nod for Omicron Booster in Kids

by Zacks Equity Research

Pfizer (PFE) and BioNTech seek to expand the EU label of their Omicron BA.4/BA.5-adapting bivalent COVID vaccine for children. It is already authorized for use in adolescents and adults.